Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 14;20(1):141.
doi: 10.1186/s12879-020-4862-x.

Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study

Sulaiman Lakoh  1   2 , Hannah Rickman  3   4   5 , Momodu Sesay  6 , Sartie Kenneh  7 , Rachael Burke  3   4   5 , Mamadu Baldeh  7 , Darlinda F Jiba  7 , Yusuf S Tejan  7 , Sonia Boyle  7 , Comfort Koroma  7 , Gibrilla F Deen  8   7 , Fenella Beynon  3   4   5
Affiliations

Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study

Sulaiman Lakoh et al. BMC Infect Dis. .

Abstract

Background: The global annual estimate for cryptococcal disease-related deaths exceeds 180,000, with three fourth occurring in sub-Saharan Africa. The World Health Organization (WHO) recommends cryptococcal antigen (CrAg) screening in all HIV patients with CD4 count < 100/μl. As there is no previous published study on the burden and impact of cryptococcal disease in Sierra Leone, research is needed to inform public health policies. We aimed to establish the seroprevalence and mortality of cryptococcal disease in adults with advanced HIV attending an urban tertiary hospital in Sierra Leone.

Methods: A prospective cohort study design was used to screen consecutive adult (18 years or older) HIV patients at Connaught Hospital in Freetown, Sierra Leone with CD4 count below 100 cells/mm3 from January to April 2018. Participants received a blood CrAg lateral flow assay (IMMY, Oklahoma, USA). All participants with a positive serum CrAg had lumbar puncture and cerebrospinal fluid (CSF) CrAg assay, and those with cryptococcal diseases had fluconazole monotherapy with 8 weeks followed up. Data were entered into Excel and analysed in Stata version 13.0. Proportions, median and interquartile ranges were used to summarise the data. Fisher's exact test was used to compare categorical variables.

Results: A total of 170 patients, with median age of 36 (IQR 30-43) and median CD4 count of 45 cells/mm3 (IQR 23-63) were screened. At the time of enrolment, 54% were inpatients, 51% were newly diagnosed with HIV, and 56% were either ART-naïve or newly initiated (≤ 30 days). Eight participants had a positive blood CrAg, giving a prevalence of 4.7% (95% CI: 2.4-9.2%). Of those with a positive CrAg, CSF CrAg was positive in five (62.5%). Five (62.5%) CrAg-positive participants died within the first month, while the remaining three were alive and established on ART at 8 weeks.

Conclusion: A substantial prevalence of cryptococcal antigenaemia and poor outcome of cryptococcal disease were demonstrated in our study. The high mortality suggests a need for the HIV programme to formulate and implement policies on screening and pre-emptive fluconazole therapy for all adults with advanced HIV in Sierra Leone, and advocate for affordable access to effective antifungal therapies.

Keywords: HIV/Cryptococcal antigenaemia/ART/newly diagnosed.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interest.

References

    1. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–881. doi: 10.1016/S1473-3099(17)30243-8. - DOI - PMC - PubMed
    1. WHO | Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. WHO. 2018; Available from: apps.who.int/iris/bitstream/handle/10665/260399/9789241550277-eng.pdf;js.... Accessed 13 Dec 2019. - PubMed
    1. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Ali M, Kambugu A, et al. Serum Cryptococcal antigen (CRAG) screening is a cost- effective method to prevent death in HIV- infected persons with CD4 <100/uL starting HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448–455. doi: 10.1086/655143. - DOI - PMC - PubMed
    1. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. Cost effectiveness of Cryptococcal antigen screening as a strategy to prevent HIV-associated Cryptococcal meningitis in South Africa. PLoS One. 2013;8(7):1–10. doi: 10.1371/journal.pone.0069288. - DOI - PMC - PubMed
    1. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med. 2017;377(3):233–245. doi: 10.1056/NEJMoa1615822. - DOI - PMC - PubMed

MeSH terms